Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.

New Support For A Controversial Mechanism Underlying An Irregular Heart Beat
The most common form of human heart beat irregularity (atrial fibrillation) can be fatal if left untreated. It has been suggested that it is caused, in part, by calcium leaking from a cellular store in heart cells, potentially through the RyR2 channel, although this mechanism remains controversial. However, a team of researchers at Baylor College of Medicine, Houston, and Dresden University of Technology, Germany, has provided support for this hypothesis by showing that the protein CaMKII can enhance RyR2-mediated calcium leak, promoting atrial fibrillation in mice.
News of the day
Genetic Variation Associated With Survival Advantage In African Americans With HIV
From the start of the HIV epidemic, it appeared that some of the people who were infected with the virus were able to ward off the fatal effects of the disease longer than others. Recent studies have begun to unravel the cause of this phenomenon, and new research suggests that African Americans with the disease have a unique survival advantage if they have both a low white blood cell count (known as leukopenia) and a genetic variation that is found mainly in persons of African ancestry. This study was prepublished online on July 20, 2009, in Blood, the official journal of the American Society of Hematology.
Public Health

States Consider Scaling Back Funding For Medicare Drug Benefit Amid Economic Crisis

At least six states have considered eliminating or reducing financial assistance for those enrolled in the Medicare prescription drug benefit program who are affected by the "doughnut hole," or gap in coverage, the AP/Boston Herald reports. According to the AP/Herald, the governors of Rhode Island and Vermont and lawmakers in South Carolina have proposed plans to eliminate such financial assistance programs, while Massachusetts has reduced funding for its program. Meanwhile, proposals in New York and Connecticut to limit financial help have been dismissed.Beneficiaries enrolled in the drug benefit have coverage until total spending reaches $2,700 and then must pay out-of-pocket for their medications until the total spending reaches $4,350, after coverage. At least 16 states provide financial help to beneficiaries who have reached the coverage gap (AP/Boston Herald, 5/27). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009